Lumibird (LTS:0FRI) 5-Year Yield-on-Cost %: 1.35 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0FRI Lumibird LTS:0FRI
80 GF Score
Price €27.50
GF Value €16.78
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lumibird 5-Year Yield-on-Cost %?

Lumibird LTS:0FRI +5.57% 80 5-Year Yield-on-Cost % is 1.35 as of Jul. 18, 2026. GuruFocus rates LTS:0FRI with a GF Score™ of 80/100 and a GF Value™ of €16.78 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Lumibird ranks worse than 67.19% on this metric.

Lumibird's yield on cost for the quarter that ended in Dec. 2025 was 1.35.


The historical rank and industry rank for Lumibird's 5-Year Yield-on-Cost % or its related term are showing as below:

LTS:0FRI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 1.35
Current: 1.35


During the past 13 years, Lumibird's highest Yield on Cost was 1.35. The lowest was 0.00. And the median was 0.00.


LTS:0FRI's 5-Year Yield-on-Cost % is ranked worse than
67.19% of 64 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.54 vs LTS:0FRI: 1.35

Lumibird  (LTS:0FRI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Lumibird 5-Year Yield-on-Cost % Related Terms


LTS:0FRI vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, Lumibird's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumibird 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lumibird's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Lumibird's 5-Year Yield-on-Cost % falls into.


LTS:0FRI
80GF Score
Lumibird LTS:0FRI
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumibird 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Lumibird is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 1.35 mean?
Lumibird (LTS:0FRI) has a 5-Year Yield-on-Cost % of 1.35 as of Jul. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lumibird and its competitors. According to the industry distribution chart, Lumibird ranks #43 out of 64 companies in the Medical Diagnostics & Research industry, placing it in the top 67.2%.
Is Lumibird's 5-Year Yield-on-Cost % too high?
Lumibird's current 5-Year Yield-on-Cost % is 1.35. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.54. Lumibird's value of 1.35 is 46.9% below this industry median. Based on the distribution chart, Lumibird ranks #43 out of 64 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lumibird has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumibird's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumibird ranks #43 out of 64 companies for 5-Year Yield-on-Cost %. This places Lumibird in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.54. Lumibird's value of 1.35 is 46.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.54, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumibird's current 5-Year Yield-on-Cost % of 1.35 is 46.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lumibird and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumibird's current 5-Year Yield-on-Cost % is 1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumibird stock overvalued right now?
Based on GuruFocus' analysis, Lumibird (LTS:0FRI) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.78, compared to a current price of €27.50 — trading 63.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 1.35 and 46.9% below the Medical Diagnostics & Research industry median of 2.54. Lumibird's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Lumibird (LTS:0FRI), the current 5-Year Yield-on-Cost % is 1.35 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumibird (LTS:0FRI) Overvalued in 2026?

Based on GuruFocus' analysis, Lumibird stock appears to be overvalued. The current stock price of €27.50 is trading 63.9% above its estimated GF Value™ of €16.78. GuruFocus considers Lumibird to be Significantly Overvalued.

Key valuation signals for LTS:0FRI:

  • 5-Year Yield-on-Cost %: 1.35
  • GF Value™: €16.78 vs. price of €27.50 (63.9% above fair value)
  • GF Score™: 80/100 with 4 warning signs
  • Industry Position: 46.9% below the Medical Diagnostics & Research median (#43 of 64)

No single metric tells the full story. See the LTS:0FRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lumibird Business Description

Address 2 rue du Paul Sabatier, Lannion, FRA, 22300
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
80GF Score

Get the complete analysis for LTS:0FRI

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€27.50
Price
€16.78
GF Value